Evidence map›Paper›PMID 33137649›Full record

ReviewCellular immunology2020

Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19.

Rajesh Rajaiah, Kandahalli V Abhilasha, Mysore A Shekar, Stefanie N Vogel, Bannikuppe S Vishwanath

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Rajesh RajaiahDepartment of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysuru, Karnataka, India. Electronic address: rajesh.r@biochemistry.uni-mysore.ac.in.
Kandahalli V AbhilashaDepartment of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysuru, Karnataka, India.
Mysore A ShekarChowdaiah Medical Center & Apoorva Diabetes Foundation, Mysuru, Karnataka, India.
Stefanie N VogelDepartment of Microbiology and Immunology, University of Maryland School of Medicine (UMSOM), Baltimore, MD, USA.
Bannikuppe S VishwanathDepartment of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysuru, Karnataka, India. Electronic address: vishmy@biochemistry.uni-mysore.ac.in.
University of Mysore · INDiabetes Foundation · INUniversity of Maryland, Baltimore · US

Funding

Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung InjuryR01AI125215 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLANCO, JORGE C, VOGEL, STEFANIE N. · 2017 to 2021
$2.7M
NIAID NIH HHS R01 AI125215
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is a global health emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The rapid worldwide spread of SARS-CoV-2 infection has necessitated a global effort to identify effective therapeutic strategies in the absence of vaccine. Among the re-purposed drugs being tested currently, hydroxychloroquine (HCQ), without or with zinc ion (Zn

Indexed as

Drug RepositioningAnti-Inflammatory AgentsAntiviral AgentsCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationHumansPandemicsPneumonia, ViralAnti-Inflammatory AgentsAntiviral AgentsCOVID-19Cytokine stormHydroxychloroquineMethotrexateSARS-CoV-2

Identifiers

PMID33137649
PMCPMC7558230
OpenAlexW3092654917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.